Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Alpha Mannosidosis Market Be Worth By 2029?

The market for alpha mannosidosis has seen significant expansion in the previous years. It is projected to increase from $15.1 billion in 2024 to $17.87 billion in 2025, with a compound annual growth rate (CAGR) of 18.3%. Factors contributing to growth during the historic period include emerging market growth, urban development, enhanced demand for artificial fibers, and governmental programs for the textile sector.

The market for alpha mannosidosis is projected to experience significant expansion in the coming years, with an estimate growth to $33.81 billion by 2029, a compound annual growth rate (CAGR) of 17.3%. Several factors fuel this predicted growth during the forecast period, including growth in global population and urbanisation, the surge in e-commerce, the increasing demand for sportswear, the rise of organized retail in emerging economies, and the growing impact of social media. Key trends anticipated during the forecast period feature an increased use of enzyme therapy, a move towards the use of hematopoietic stem cell transplantation and a wider adoption of cisterna magna infusion.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp

What Underlying Factors Are Supporting The Alpha Mannosidosis Market Growth?

The alpha mannosidosis market is poised for growth, driven by the escalating demand for precision medicine. This personalized approach to healthcare takes into account the unique genetic, environmental, and lifestyle factors in patients, which aids in optimizing treatment and prevention strategies. The burgeoning popularity of precision medicine can be attributed to innovative advances in genomic technologies and data analytics, which facilitate more precise identification of genetic variations and their health impacts. Coupled with a growing appetite for tailored treatment solutions and an increased understanding of the shortcomings of standard approaches, there’s heightened interest in individualized healthcare. Precision medicine facilitates the creation of targeted therapies, customized to specific genetic mutations and patient profiles linked to this rare disease. As illustrated by data from the Personalized Medicine Coalition (PMC), a U.S. based non-profit consortium, in 2023, the FDA approved 16 novel personalized treatments for rare diseases in February 2024, a significant increase from mere six approvals in 2022. Hence, the burgeoning demand for precision medicine is fueling the expansion of the alpha mannosidosis market.

Which Segmentation Categories Are Highlighted In The Alpha Mannosidosis Market Analysis?

The alpha mannosidosis market covered in this report is segmented –

1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies

2) By Indication: Type I, Type II, Type III

3) By End-User: Hospitals, Speciality Clinics

Subsegments:

1) By Bone Marrow Transplant (BMT): Autologous BMT, Allogeneic BMT

2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes, Long-acting Enzyme Formulations

3) By Other Therapies: Symptomatic Treatments, Gene Therapy, Supportive Care

Which Market Trends Are Expected To Define The Future Of The Alpha Mannosidosis Market?

Leading businesses in the alpha mannosidosis market are prioritizing the creation of enzyme replacement therapies for this uncommon ailment. The therapy operates by introducing exogenous alpha-mannosidase which decreases the build-up of mannose-dense oligosaccharides in numerous tissues and organs. This build-up is typical of alpha-mannosidosis and integral to the disease’s detrimental effects. For instance, Chiesi Global Rare Diseases, a pharmaceutical company based in the U.S., launched Lamzede (velmanase alfa) in February 2023. This was the first enzyme replacement therapy approved in the U.S. for alpha-mannosidosis – a rare genetic disorder characterized by a deficiency of the alpha-mannosidase enzyme in the body and its effects beyond the central nervous system. Lamzede works by replicating the functions of the body’s own alpha-mannosidase enzyme, thus restoring regular cellular activity in patients. Injections of 10 mg Lamzede are administered to patients weekly.

Which Organizations Are At The Forefront Of The Alpha Mannosidosis Market?

Major companies operating in the alpha mannosidosis market include Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Merck, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd, Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma Plc, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bayer AG, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca plc, Biogen SA, Sanofi, Adcock Ingram

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Alpha Mannosidosis Market?

North America was the largest region in the alpha mannosidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=4093&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model